Dopaminergic agonists in the treatment of Parkinson's disease: a review.
Dopaminergic agonists represent an important class of drugs in Parkinson's Disease, useful: a) in delaying the beginning of L-dopa therapy; b) in supporting it, reducing its dosage and widen the therapeutic window; c) moreover, as the disease advances, in trying to treat motor fluctuations. Authors describe briefly the problems caused by long term L-dopa therapy, and analyze, separately, the characteristics of the most important dopaminergic agonists currently utilized in the treatment of PD.
Piccoli
F
F
Institute of Neuropsychiatry, University of Palermo, Italy.
Riuggeri
R M
RM
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D017447:Receptors, Dopamine D1 / Q000819:agonists; D017448:Receptors, Dopamine D2 / Q000819:agonists
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D007980:Levodopa